Feb 22, 2017 at 20:38 | Source: PTI
The Delhi High Court today told Swiss pharma major Roche that it "cannot hang on to" breast cancer drug Trastuzumab, innovated by it, for the rest of its life after having enjoyed the fruits of its patent.
Feb 08, 2017 at 10:12 | Source: PTI
"As per Indian Council of Medical Research's National Cancer Registry programme, there would be an estimated 1,28,451 cases of mouth cancer, 1,79,790 of breast cancer and 1,04,060 of cervical cancer in the country by 2020.
Jan 18, 2017 at 15:16 | Source: Moneycontrol.com
Zydus Cadila has received the final approval from the USFDA to market Methotrexate tablets USP, 2.5 mg, a chemotherapy drug used for leukemias, lymphomas, breast cancer, lung cancer, and head and neck cancer and other cancers.
Jan 12, 2017 at 08:43 | Source: CNBC-TV18
Following US president-elect Donald Trumps explosive speech last night where he lambasted the domestic pharma companies for outsourcing work, pharma stocks are likely to be in limelight today.
Jan 12, 2017 at 08:21 | Source: Moneycontrol.com
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Dec 27, 2016 at 15:41 | Source: Moneycontrol.com
This study was the last major step of a multiple-phased programme to demonstrate that proposed biosimilar trastuzumab meets the criteria for equivalence in comparison to branded trastuzumab.
Oct 22, 2016 at 17:42 | Source: PTI
PTI,Yoga guru Baba Ramdev,Patanjali Group,United States,US visa,Chief Minister Shivraj Singh Chouhan,Madhya Pradesh,Finance Minister Arun Jaitley
Sep 19, 2016 at 16:40 | Source: PTI
Glenmark Pharmaceuticals todaysaid it has entered into an agreement with US-based ParticleSciences Inc to develop and market a generic version ofCelgene's ABRAXANE which is used in treatments of breast andlung cancers.
Aug 26, 2016 at 09:13 | Source: CNBC-TV18
The European Medicines Agency (EMA) has accepted to review Mylan and Biocons application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers.
Jun 04, 2016 at 15:30 | Source: PTI
Global pharma major Mylan Inc, and Biocon have confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms, incomparison to Roche's branded Herceptin used for treatment of cancer